ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
4,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
4,2,Periorbital oedema,Ocular disorders NEC,Eye disorders NEC,Eye,N
5,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
6,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
6,2,Pigmentation disorder,Pigmentation changes NEC,Pigmentation disorders,Skin,N
7,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
8,1,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
9,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
9,2,Headache,Headaches NEC,Headaches,Nerv,N
9,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
10,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
10,2,Headache,Headaches NEC,Headaches,Nerv,N
10,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
11,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
11,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
11,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
12,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
13,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
14,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
15,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
15,2,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
16,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
17,1,Application site laceration,Application site reactions,Administration site reactions,Genrl,N
